Evaluating Setmelanotide Treatment for Bardet-Biedl Syndrome and Severe Genetic Obesity in Real-World Clinical Practice
A Prospective Study on Effectiveness, Safety, and Patient-Reported Outcomes
Led by Tom Hühne · Updated on 2026-06-29
200
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the use of setmelanotide, a melanocortin-4 receptor MC4R agonist, in people with Bardet-Biedl syndrome BBS and other rare genetic disorders causing severe early-onset obesity and excessive hunger. These conditions involve defects in the MC4R pathway, which regulates appetite and energy balance. While clinical trials have shown setmelanotides effects, this study focuses on understanding its impact under real-world clinical conditions, including safety and patient experience.
Participants will receive setmelanotide according to approved labeling and their physicians discretion, reflecting routine clinical practice. The study is designed as a registry to collect long-term data on setmelanotide treatment and may include other MC4R agonists as they become available. Data collection occurs during regular outpatient visits at University Hospital Essen, tracking treatment persistence and metabolic outcomes.
Throughout the study, participants will have routine clinical assessments including body weight, BMI, lipid profiles, liver fat measurements, and quality of life evaluations. Researchers will also monitor safety, tolerability, cognitive changes, brain connectivity, and hormonal changes over several years, with outcome measurements taken up to 72 months. The study gathers both clinical and patient-reported data to understand treatment effects in everyday care.
CONDITIONS
Brief Title
Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity
Research Team
T
Tom Hühne, Dr. med.
L
Lars Dinkelbach, Dr. med.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Clinical phenotype corresponding to Bardet-Biedl Syndrome
Genetic testing with notable finding
You will not qualify if you...
Patients younger than the age approved for treatment with setmelanotide
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Study to Create a Clinical and Genetic Database for Hepato-Renal Fibrocystic Diseases Including ARPKD and Related Conditions
French Cohort Study for Bardet-Biedl Syndrome and Alstrm Syndrome to Improve Care and Understand Disease Progression
GROWing Up With Rare Genetic Syndromes Understanding Medical Needs of Adults with Complex Genetic Conditions
Coordination of Rare Diseases at Sanford Registry for Individuals with Rare and Undiagnosed Conditions
Evaluating Setmelanotide Treatment for Bardet-Biedl Syndrome and Severe Genetic Obesity in Real-World Clinical Practice
A Prospective Study on Effectiveness, Safety, and Patient-Reported Outcomes
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Setmelanotide, a Novel, Selective Melanocortin Receptor-4 Agonist Exerts Anti-inflammatory Actions in Astrocytes and Promotes an Anti-inflammatory Macrophage Phenotype.
Alwin Kamermans, Tom Verhoeven, Bert van Het Hof...
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.